Internal request: Suggestion was made to review and revise the systemic therapy regimens used for the treatment of gastric cancer.

Based upon discussion, the panel consensus was to revise the systemic therapies list as follows:

### Preoperative Chemoradiation

- **Preferred Regimens**
  - Paclitaxel and carboplatin (category 1)
  - Cisplatin and fluorouracil (category 1)
  - Oxaliplatin and fluorouracil changed from category 2A to a category 1 recommendation.
  - Cisplatin and capecitabine
  - Oxaliplatin and capecitabine

- **Other Regimens**
  - Irinotecan and cisplatin (category 2B)
  - Docetaxel or paclitaxel and fluoropyrimidine (category 2B)

- The following combinations were removed:
  - Paclitaxel and cisplatin
  - Carboplatin and fluorouracil
  - Oxaliplatin, docetaxel, and capecitabine

### Perioperative Chemotherapy

- Fluorouracil and cisplatin (category 1) was added

### Postoperative Chemotherapy

- Capecitabine and cisplatin was added

For the preoperative chemoradiation, perioperative chemotherapy, and postoperative chemotherapy references, see the NCCN 1.2013 Guidelines for Gastric cancer (www.nccn.org).


Internal request: Suggestion was made to review and revise the systemic therapy regimens used for the treatment of gastric cancer.

**Panel Discussion**

Based upon discussion, the panel consensus was to revise the systemic therapies as follows:

**Sequential Chemotherapy and Chemoradiation**

- This section and the following combinations were removed:
  - Irinotecan and cisplatin
  - Paclitaxel and cisplatin
  - Docetaxel and cisplatin
  - 5-fluorouracil and cisplatin; 5-fluorouracil and paclitaxel

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>Vote</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAST-E (2 of 13) (continued) Internal request:</td>
<td>Based upon discussion, the panel consensus was to revise the systemic therapies as follows: Sequential Chemotherapy and Chemoradiation</td>
<td>15 0 7</td>
<td>7</td>
</tr>
</tbody>
</table>
Based upon discussion, the panel consensus was to revise the first-line systemic therapies for metastatic or locally advanced cancer as follows:

**First-line Therapy**

- **Preferred Regimens**
  - DCF (docetaxel, cisplatin and fluorouracil) (category 1)
  - DCF modifications
    - Docetaxel, oxaliplatin and fluorouracil
    - Docetaxel, carboplatin and fluorouracil (category 2B)
  - ECF (epirubicin, cisplatin and fluorouracil) (category 1)
  - ECF modifications (category 1)
    - Epirubicin, oxaliplatin and fluorouracil
    - Epirubicin, cisplatin and capecitabine
    - Epirubicin, oxaliplatin and capecitabine
  - Fluoropyrimidine (fluorouracil or capecitabine) and cisplatin (category 1)
  - Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin
  - Fluorouracil and irinotecan

- **Other Regimens**
  - Paclitaxel with cisplatin or carboplatin
  - Docetaxel with cisplatin
  - Docetaxel and irinotecan (category 2B)
  - Fluoropyrimidine (fluorouracil or capecitabine)
  - Docetaxel
  - Paclitaxel

For the first-line therapy references, see the NCCN 1.2013 Guidelines for Gastric Cancer (www.nccn.org)
Based upon discussion, the panel consensus was to revise the second-line therapies and alternative regimens for metastatic or locally advanced cancer as follows:

**Second-line Therapy**

- **Preferred Regimens**
  - Docetaxel (category 2B)
  - Paclitaxel (category 2B)
  - Irinotecan (category 2B)

- **Other Regimens**
  - Irinotecan and cisplatin
  - Irinotecan and fluoropyrimidine (fluorouracil or capecitabine) (category 2B)
  - Docetaxel and irinotecan (category 2B)

- The following combinations were removed:
  - Irinotecan and mitomycin

**Alternative regimens for consideration (these may be combined with other regimens when appropriate)**

- The following combinations were removed:
  - Gemcitabine, fluorouracil, and leucovorin
  - Mitomycin, cisplatin, and fluorouracil
  - Pegylated liposomal doxorubicin, cisplatin and fluorouracil
  - Erlotinib

For the second-line therapy and alternative regimens references, see the NCCN 1.2013 Guidelines for Gastric cancer (www.nccn.org)